Clinical features, diagnostics and treatment of FGF23 secreting tumors: series of 40 clinical cases
Problems of Endocrinology · 2023
DOI: 10.14341/probl13221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Problems of Endocrinology, 2023. Verfasst von S A Gronskaia und 23 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Research Center. Hauptthemen laut MEDLINE: Neoplasms, Connective Tissue, Hypophosphatemia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Tumor-induced osteomalacia is an acquired rare disease manifested by hypophosphatemic osteomalacia due to excessive secretion of fibroblast growth factor 23 (FGF23). FGF 23 is a non-classical hormone secreted by bone tissue (osteocytes) and regulates phosphorus metabolism. The aim of this work is to present clinical experience in the diagnosis, treatment and rehabilitation of patients with tumor-induced osteomalacia. Materials and methods : 40 patients with clinically-confirmed tumor-induced osteomalacia were included in the study, 34 of whom had the tumor localized, 27 underwent surgical treatment and 21 achieved stable remission.
Results
The median age was 48 [41; 63] years, 43% were men, the time left from the the onset of the disease was 8 [4; 10] years. Biochemical findings were hypophosphatemia 0.47 [0.4; 0.53] mmol/l, a decrease in the tubular reabsorption phosphate 62 [52; 67]%, and an increase in alkaline phosphatase of 183 [112; 294] units/l. At the time of diagnosis, 100% had multiple pathological fractures, only 10% could move independently, and 77.5% classified the pain as unbearable (8–10 points according to the 10-point pain syndrome scale ). Among the methods used to detect tumors, the most sensitive were scintigraphy with tectrotide with SPECT/CT 71.4% (20/28) and MRI 90% (18/20). In 35% of cases, the tumor was localized in soft tissues and in 65% in bone tissue; The tumor was most often detected in the lower extremities, followed by the head in frequency of localization. 18 patients currently have no remission and they receive conservative treatment (phosphorus and alfacalcidol n=15 and burosumab n=3). In case of achieving remission (n=21), regression of clinical symptoms and restoration of bone and muscle mass was observed. Extensive excision of the tumor without prior biopsy resulted in the best percentage of remission — 87%.
Conclusion
Tumor-induced osteomalacia is characterized by severe damage to bone and muscle tissue with the development of multiple fractures, muscle weakness and severe pain syndrome. In laboratory diagnostics, attention should be paid to hypophosphatemia, a decrease in the tubular reabsorption phosphate index and increased alkaline phosphatase. The use of functional diagnostic methods with a labeled somatostatin analogue to the subtype 2 receptor and MRI with contrast enhancement are the most accurate methods of topical diagnostics. In case of localization of the tumor, a wide excision without a preliminary biopsy is recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Endocrinology Research Center.
- N.N. Priorov National Medical Research Center of Traumatology and Orthopaedics.
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry.
- V.A. Nasonova Research Institute of Rheumatology.
- North-Western State Medical University named after I.I. Mechnikov.
Zitieren
APA
Gronskaia, S. A., Belaya, Z. E., Rozhinskaya, L. Y., Melnichenko, G. A., Dubovitskaya, T. A., Mamedova, E. O., Rodionova, S. S., Buklemishev, Y. V., Pigarova, E. A., Degtyarev, M. V., Babaeva, D. M., Vladimirova, V. P., Tarbaeva, N. V., Serzhenko, S. S., Grigoriev, A. Y., Dzeranova, L. K., Karpenko, V. Y., Karasev, A. L., Fedotov, R. N., …, & Dedov, I. I. (2023). Clinical features, diagnostics and treatment of FGF23 secreting tumors: series of 40 clinical cases. Problems of Endocrinology. https://doi.org/10.14341/probl13221
Vancouver
Gronskaia SA, Belaya ZE, Rozhinskaya LY, Melnichenko GA, Dubovitskaya TA, Mamedova EO, et al. Clinical features, diagnostics and treatment of FGF23 secreting tumors: series of 40 clinical cases. Problems of Endocrinology. 2023. doi:10.14341/probl13221
BibTeX
@article{Gronskaia2023,
author = {Gronskaia, S A and Belaya, Zh E and Rozhinskaya, L Ya and Melnichenko, G A and Dubovitskaya, T A and Mamedova, E O and Rodionova, S S and Buklemishev, Yu V and Pigarova, E A and Degtyarev, M V and Babaeva, D M and Vladimirova, V P and Tarbaeva, N V and Serzhenko, S S and Grigoriev, A Yu and Dzeranova, L K and Karpenko, V Yu and Karasev, A L and Fedotov, R N and Uliyanova, I N and Toroptsova, N V and Lesnyak, O M and Mokrysheva, N G and Dedov, I I},
title = {Clinical features, diagnostics and treatment of FGF23 secreting tumors: series of 40 clinical cases},
journal = {Problems of Endocrinology},
year = {2023},
doi = {10.14341/probl13221}
}
EUVIMED